EKF Diagnostics (LON:EKF) Posts Quarterly Earnings Results

EKF Diagnostics (LON:EKF) announced its earnings results on Tuesday. The company reported GBX 1.38 ($0.02) earnings per share for the quarter, Digital Look Earnings reports. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%.

EKF Diagnostics Stock Performance

Shares of EKF Diagnostics stock traded down GBX 0.80 ($0.01) during midday trading on Thursday, hitting GBX 21.20 ($0.27). The company had a trading volume of 3,854,483 shares, compared to its average volume of 569,733. EKF Diagnostics has a 1-year low of GBX 18.40 ($0.24) and a 1-year high of GBX 33.80 ($0.44). The business’s 50 day simple moving average is GBX 23.23 and its two-hundred day simple moving average is GBX 25.85. The stock has a market cap of £94.23 million, a PE ratio of 19.73 and a beta of 0.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.60 and a quick ratio of 1.77.

Insider Buying and Selling at EKF Diagnostics

In other EKF Diagnostics news, insider Gavin T. Jones purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, March 25th. The shares were purchased at an average price of GBX 22 ($0.28) per share, for a total transaction of £11,000 ($14,162.48). Insiders own 5.24% of the company’s stock.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.